Skip to content
Screener

Candel Therapeutics, Inc. CADL Cash Flow Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$38.91M-711%-$8.86M-220%-$29.5M-110%-$11.27M-5.9%-$4.8M+78.4%
$200K0.0%$149K-39.2%$163K-33.5%$200K0.0%$200K0.0%
$2.86M+172%$1.45M+362%$1.29M+3.7%$1.16M-1.8%$1.05M-43.0%
-$17.18M-93.3%-$18.04M-109%-$10.57M-81.8%-$10.24M-55.7%-$8.89M-43.4%
$69K+123%$675K+22,400%$409K+13,533%$144K$31K+417%
-$69K-123%-$675K-22,400%-$409K-13,533%-$117K-$31K-417%
$23.98M+37.5%$93.82M+5,117%$43.9M-52.2%$0-100%$17.44M+797%
$6.73M-21.0%$75.1M+816%$32.92M-61.8%-$13.72M-180%$8.52M+300%
-$17.25M-93.4%-$18.71M-117%-$10.98M-88.7%-$10.38M-57.9%-$8.92M-43.8%

FAQ

How much cash does Candel Therapeutics, Inc. generate?
Candel Therapeutics, Inc. (CADL) generated -$56.0M in operating cash flow over the trailing twelve months.
What is Candel Therapeutics, Inc.'s free cash flow?
After $1.3M of capital expenditures, Candel Therapeutics, Inc.'s free cash flow was -$57.3M over the trailing twelve months, down 91.5% year over year.
Where does Candel Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.